Saccharomyces boulardii

Probioticprobiotic yeastStrong dose evidence

Also known as: S. boulardii, Saccharomyces cerevisiae var. boulardii, CNCM I-745, Florastor strain, probiotic yeast

Add to a formula

Saccharomyces boulardii is a probiotic yeast rather than a bacterium, originally isolated from lychee and mangosteen skins. Because it is a fungus, antibacterial antibiotics do not kill it, which is why it is the classic choice alongside antibiotic courses and in travel formulas. A 2010 systematic review and meta-analysis in adults covered antibiotic-associated diarrhea, traveler's diarrhea, and Helicobacter pylori adjunct trials, most using 250–500 mg (roughly 5–10 billion CFU) daily. It does not colonize permanently and clears within days after stopping.

Research summary

Studied for binding of bacterial toxins, support of intestinal enzyme activity, and modulation of inflammatory signaling; unaffected by antibacterial antibiotics.

Dosage

Daily amounts, of compound. CFU shown in billions.

Lowest studiedTypical rangeHighest studiedUpper limit
5 B CFU5–10 B CFU

Amounts are in billions of CFU (enter 5 for 5 billion). Unlike bacterial rows, lyophilized S. boulardii is typically supplied at about 20 billion CFU per gram, so 5–10 billion CFU corresponds to roughly 250–500 mg of raw material (about 50 mg per billion CFU). Manufacturers add a 20–50% overage at fill; state CFU at manufacture or at expiry on the label. Can be taken during an antibiotic course without spacing.

Standardization: Lyophilized yeast; CFU per gram on CoA (commonly about 20 billion CFU/g)

Source material: freeze-dried culture

As supplied: Assumes about 20 billion CFU/g lyophilized yeast (50 mg per billion CFU), consistent with 250 mg ≈ 5 billion CFU; adjust to supplier CoA.

Format suitability

  • Capsule
  • Powder
  • Tablet
  • Softgel
  • Gummy
  • Liquid

Heat- and moisture-sensitive; capsule or dry powder only. More acid-stable than most bacterial probiotics.

Formulation notes

Antifungal drugs inactivate it; separate from antifungals. Not appropriate for immunocompromised users or those with central venous catheters because of rare fungemia reports. Unaffected by antibacterial antibiotics, so no dose spacing is needed.

Sources

  1. NIH ODS — Probiotics Fact Sheet for Health ProfessionalsNIH ODS
  2. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. (McFarland 2010)PubMed

Related ingredients